PSORIASIS
Conditions
Sponsors
Wyeth Pharmaceuticals France
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: · Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA · Eligible for treatment with etanercept according to Summary of Product Characteristics (SmPC), and applicable local guidelines. · Aged 18 years or more · Willing and able to self-inject etanercept. · Able to store test drug at 2-8°C. · Negative serum ß-human chorionic gonadotropin (ß-HCG) pregnancy test at baseline (week 0) for all women of childbearing potential. Sexually active women of childbearing potential must use a medically acceptable form of contraception. Medically acceptable forms of contraception include oral contraceptives, injectable or implantable methods, intrauterine devices, or properly used barrier contraception. Sexually active men must agree to use a reliable form of contraception during the study. · Capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol-specific procedures are performed. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: · Prior experience of biologic treatment for their Psoriasis including etanercept. · Sepsis or risk of sepsis. · Current or recent infections, including chronic or localized. · Latex sensitivity. · Vaccination with live vaccine in last 4 weeks, or expected to require such vaccination during the course of the study.Patients with the following conditions or risk factors should only be entered into the study if the investigator has conducted and documented a full risk/benefit evaluation: · History of recurring or chronic infection, or underlying condition which may predispose patients to infections e.g. Tuberculosis (TB) infection (Note: follow local country guidelines for appropriate screening and treatment of tuberculosis in the setting of anti-TNF therapy), serious infection (infection associated with hospitalization and/or intravenous antibiotics) within 1 month of test article administration or active infection at screening, open cutaneous ulcers, known human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) positive. · Current or prior history of blood dyscrasias. Abnormal safety baseline blood test e.g. hemoglobin =85 g/L; hematocrit =27 %; platelet count =125 x 109 /L; white blood cell count =3.5 x 109 /L; serum creatinine =175 µmol/L; aspartate aminotransferase (AST [SGOT]) and alanine aminotransferase (ALT [SGPT]) =2 times the laboratory’s upper limit of normal. · Pre-existing or recent onset CNS demyelinating disease. · Cardiovascular conditions, e.g., myocardial infarction within 12 months of the screening visit, unstable angina pectoris, class III or IV congestive heart failure as defined by the New York Heart Association classification (4) or decompensated congestive heart failure. · Uncontrolled conditions, e.g., diabetes mellitus, hypertension (defined as screening systolic blood pressure > 160 mm Hg or screening diastolic blood pressure > 100 mm Hg), severe pulmonary disease requiring hospitalization or supplemental oxygen. · At increased risk of malignancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare patient satisfaction with two different delivery devices for etanercept after 12 weeks of use, using a 10 point scale form totally dissatisfied to totally satisfied.;Secondary Objective: · To compare patient satisfaction with the two different delivery devices using a dichotomous Yes or No. · To identify patient and device attributes associated with patient satisfaction. · To compare device attributes and patient perceptions with two different delivery devices for etanercept after 4 & 12 weeks of use. · To identify patient attributes associated with patient perceptions.;Primary end point(s): The primary endpoint will be patient satisfaction at week 12. This endpoint will be measured by asking patients: “How satisfied are you with your injection device?”, using a 0-10 point scale from totally dissatisfied to totally satisfied. If there is no evaluation available after the first administration of test agent, the subject will not be considered for the analysis of the primary endpoint. | — |
Countries
Belgium, Denmark, Finland, France, Germany, Greece, Netherlands, Spain, Sweden
Outcome results
None listed